City of Hope licenses CAR T therapy to Chimeric Therapeutics

By The Science Advisory Board staff writers

September 21, 2020 -- City of Hope has licensed intellectual property for its chlorotoxin chimeric antigen receptor (CLTX-CAR) T-cell therapy to Chimeric Therapeutics.

Chimeric, an Australian biotechnology company, has acquired the exclusive worldwide rights to develop and commercialize certain patents related to City of Hope's CLTX-CAR T cells, as well as further develop the therapy for other cancers.

Uniquely, the CLTX-CAR uses a synthetic 36-amino acid peptide sequence first isolated from death stalker scorpion venom and is engineered to serve as the CAR recognition domain. The CLTX CAR T-cell therapy was developed and tested by City of Hope researchers. In early studies, the team found that CLTX-CAR T cells recognized and killed broad populations of glioblastoma cells while ignoring nontumor cells in the brain and other organs. The therapy is currently being evaluated in a phase I clinical trial to treat glioblastoma.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here